The development cohort was slightly older than the validation cohort (mean [SD] age, 74.1 [12.8] years vs 71.9 [14] years), had lower albuminuria (median [IQR] albumin-creatinine ratio, 7.6 [1.7-56.2] mg/mmol vs 19.7 [3.3-136.1] mg/mmol), and included more people with diabetes (9886 [67.6%] vs 1448 [63.1%]) and cardiovascular disease (8285 [56.7%] vs 796 [34.7%]) (Table). The gene discussed is ALB; the disease is diabetes mellitus.